Prof. Dr. Dr. Heinz Peter Vollmers

Prof. Dr. Dr. Heinz Peter Vollmers
Research Group “Cell and Tumor Biology”, Institute of Pathology, University of
Wuerzburg, Josef-Schneider-Str. 2, D-97080 Würzburg, Germany
__________________________________________________________________________
2008
Ausgewählte Publikationen
Vollmers HP, Brändlein S.
Natural monoclonal antibodies and cancer.
Recent Patents Anticancer Drug Discov. 2008 Jun;3(2):84-7.
Rauschert N, Brändlein S, Holzinger E, Hensel F, Müller-Hermelink HK, Vollmers
HP. A new tumor-specific variant of GRP78 as target for antibody-based therapy.
Lab Invest. 2008 Apr;88(4):375-86.
2007
Brandlein S, Rauschert N, Rasche L, Dreykluft A, Hensel F, Conzelmann E, Muller-
Hermelink HK, Vollmers HP.
The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized lowdensity
lipoprotein.
Mol Cancer Ther. 2007 Jan;6(1):326-33.
Vollmers HP, Brändlein S.
Natural antibodies and cancer.
J Autoimmun. 2007 Dec;29(4):295-302.
Vollmers HP, Brändlein S.
Tumors: too sweet to remember?
Mol Cancer. 2007 Dec 4;6:78.
2006
Vollmers H.P. and Brändlein, S.
Natural IgM antibodies: The orphaned molecules in immune surveillance.
Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):755-65.
Vollmers H.P. and Brändlein, S.
Natural IgM antibodies: from parias to parvenus.
Histol Histopathol. 2006 Dec;21(12):1355-66.
2005
Illert B, Otto C, Vollmers H.P., Hensel F, Thiede A, Timmermann W.
Human antibody SC-1 reduces disseminated tumor cells in nude mice with human
gastric cancer.
Oncol Rep. 2005 Apr;13(4):765-70.
H.P. Vollmers: Ausgewählte Publikationen

Vollmers H.P. and Brändlein, S.
„Death by stress: natural IgM induced apoptosis“.
Methods Find. Exp. Clin. Pharmacol. 27(3): 1-7, 2005.
Vollmers H.P. and Brändlein, S.
The "early birds": natural IgM antibodies and immune surveillance.
Histol Histopathol. 2005 Jul;20(3):927-37.
2004
Brändlein, S., Pohle, T., Vollmers, C., Wozniak, E., Ruoff, N., Bernhardt, W., Müller-
Hermelink, H.K. and Vollmers, H.P.
„CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human
monoclonal antibody PAM-1.“
Oncol. Rep. 11(4): 777-784, 2004.
Pohle T, Brändlein S, Ruoff N, Muller-Hermelink HK, Vollmers H.P.
„Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid
accumulation.
Cancer Res. 64(11): 3900-3906; 2004.
Brändlein S. and Vollmers H.P.
„Natural IgM antibodies, the ignored weapons in tumour immunity.“
Histol Histopathol. 19(3): 897-905, 2004.
2003
Brändlein S., Beyer I., Eck M., Bernhardt W., Hensel F., Müller-Hermelink H.K. and
Vollmers H.P.
CFR-1, a new marker for precancerous epithelial lesions defined by the human
monoclonal antibody PAM-1.
Cancer Res 63:2052-2061, 2003.
Brändlein, S., Pohle, T., Ruoff, N., Wozniak, E., Müller-Hermelink, H.K. and
Vollmers, H.P.
Natural IgM Antibodies and Immunosurveillance Mechanisms against Epithelial
Cancer Cells in Humans.
Cancer Res. 63, 15. November 2003.
2002
Vollmers, H.P. and Brändlein, S.
Nature´s best weapons to fight cancer. Revival of human monoclonal IgM antibodies.
Hum Antibodies 11: 131-142, 2002.
Brändlein S., Lorenz J., Ruoff N., Hensel F., Beyer I., Müller J., Neukam K., Illert B.,
Eck M., Müller-Hermelink H.K. and Vollmers H.P.
Human monoclonal IgM antibodies with apoptotic activity isolated from cancer
patients.
Hum Antibodies 11:107-119, 2002.
H.P. Vollmers: Ausgewählte Publikationen

2001
Hensel, F., Brändlein, S., Eck ,M., Schmidt, K., Krenn, V., Kloetzer, A., Bachi, A.,
Mann, M., Muller-Hermelink, H.K. and Vollmers, H.P.
A novel proliferation-associated variant of CFR-1 defined by a human monoclonal
antibody.
Lab Invest.: 81:1097-1108, 2001
Hensel, F., Hermann, R., Brändlein, S., Krenn, V., Schmausse,r B., Geis, S., Muller-
Hermelink, H.K. and Vollmers, H.P.
Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on
stomach carcinoma cells involved in antibody SC-1-induced apoptosis.
Lab Invest. 81:1553-15 63. 2001
H.P. Vollmers: Ausgewählte Publikationen